BioLineRx pipeline returns to the winner’s circle
After disappointing investors in March by terminating a Phase 2/3 clinical trial of an anti-psychotic drug candidate for the treatment of schizophrenia, BioLineRx (NASDAQ:BLRX; TASE:BLRX) bounced back...
View ArticleJames Gandolfini’s death highlights risk factors for heart attack
The recent and widely reported death of actor James Gandolfini highlights the need to aggressively address the known risk factors for heart attack and sudden cardiac death. George Jackowski “Omega-3...
View ArticleInterface, Q3 in Kinesyx development pact
Closely-held Interface Biologics of Toronto and Q3 Medical Devices have signed a joint development and commercialization agreement to combine Interface’s Kinesyx bioactive oligomers with the balloon...
View ArticleAmarantus posts positive preclinical data for retinitis pigmentosa
Amarantus BioScience Holdings (OTCQB:AMBS) has announced positive effects of Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) for the protection from vision loss in an animal model of...
View Article
More Pages to Explore .....